Catalent (NYSE:CTLT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note published on Sunday morning. The firm issued a hold rating on the stock.

Several other research firms have also recently weighed in on CTLT. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Stock Performance

CTLT opened at $63.48 on Friday. The business has a fifty day moving average price of $61.94 and a 200 day moving average price of $60.27. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent has a 12 month low of $41.15 and a 12 month high of $63.50. The stock has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.69 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the company earned ($0.10) EPS. Sell-side analysts expect that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.31% of the stock is owned by company insiders.

Hedge Funds Weigh In On Catalent

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brooklyn Investment Group acquired a new position in Catalent in the 3rd quarter valued at $31,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent in the third quarter valued at about $53,000. Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the period. Intact Investment Management Inc. purchased a new position in Catalent during the third quarter worth about $73,000. Finally, GAMMA Investing LLC lifted its position in Catalent by 26.9% in the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after purchasing an additional 278 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.